191 related articles for article (PubMed ID: 23473771)
1. Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy.
Gullo G; Bettio D; Zuradelli M; Masci G; Giordano L; Bareggi C; Tomirotti M; Salvini P; Runza L; La Verde N; Santoro A
Breast; 2013 Apr; 22(2):190-193. PubMed ID: 23473771
[TBL] [Abstract][Full Text] [Related]
2. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
3. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Han HS; Kim JS; Park JH; Jeon YK; Lee KW; Oh DY; Kim JH; Park SY; Im SA; Kim TY; Park IA; Bang YJ
J Korean Med Sci; 2009 Oct; 24(5):910-7. PubMed ID: 19794992
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
Köstler WJ; Brodowicz T; Hudelist G; Rudas M; Horvat R; Steger GG; Singer CF; Attems J; Rabitsch W; Fakhrai N; Elandt K; Wiltschke C; Hejna M; Zielinski CC
J Cancer Res Clin Oncol; 2005 Jul; 131(7):420-8. PubMed ID: 15864644
[TBL] [Abstract][Full Text] [Related]
6. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
7. Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.
Xiao C; Gong Y; Han EY; Gonzalez-Angulo AM; Sneige N
Ann Oncol; 2011 Jul; 22(7):1547-1553. PubMed ID: 21239403
[TBL] [Abstract][Full Text] [Related]
8. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
Gullo G; Bettio D; Torri V; Masci G; Salvini P; Santoro A
Invest New Drugs; 2009 Apr; 27(2):179-83. PubMed ID: 18663410
[TBL] [Abstract][Full Text] [Related]
9. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
[TBL] [Abstract][Full Text] [Related]
10. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
[TBL] [Abstract][Full Text] [Related]
11. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
[TBL] [Abstract][Full Text] [Related]
12. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
13. [Molecular protocol for HER2/neu analysis in breast carcinoma].
Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
[TBL] [Abstract][Full Text] [Related]
14. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
15. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
Chan A; McGregor SR
Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
[TBL] [Abstract][Full Text] [Related]
18. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
